Search results for "azo"

showing 10 items of 5680 documents

Handling Metalloproteinases.

2016

Substrate cleavage by metalloproteinases involves nucleophilic attack on the scissile peptide bond by a water molecule that is polarized by a catalytic metal, usually a zinc ion, and a general base, usually the carboxyl group of a glutamic acid side chain. The zinc ion is most often complexed by imidazole nitrogens of histidine side chains. This arrangement suggests that the physiological pH optimum of most metalloproteinases is in the neutral range. In addition to their catalytic metal ion, many metalloproteinases contain additional transition metal or alkaline earth ions, which are structurally important or modulate the catalytic activity. As a consequence, these enzymes are generally sen…

0301 basic medicineMetal ions in aqueous solutionGlutamic AcidMatrix metalloproteinaseHydrogen-Ion ConcentrationBiochemistryCombinatorial chemistryCatalysisMetal03 medical and health scienceschemistry.chemical_compoundZinc030104 developmental biologychemistryStructural Biologyvisual_artvisual_art.visual_art_mediumMetalloproteasesMoleculeImidazolePeptide bondAnimalsHumansAstacinHistidineCurrent protocols in protein scienceLiterature Cited
researchProduct

In vitro activity of anidulafungin in combination with amphotericin B or voriconazole against biofilms of five Candida species

2016

Objectives: To evaluate the in vitro activity of anidulafungin combined with amphotericin B or voriconazole against Candida spp. biofilms. Methods: Four Candida albicans, four Candida tropicalis, four Candida glabrata, two Candida parapsilosis and two Candida orthopsilosis blood isolates were tested by the microdilution chequerboard method combined with the XTT metabolic assay. Biofilm MIC was defined as the lowest concentration producing 50% metabolic inhibition with respect to control (BMIC50). Concentrations in the combinations ranged from 1/8xBMIC(50) to 4xBMIC(50) found for each antifungal tested alone. Results: Anidulafungin plus amphotericin B acted synergistically against C. albican…

0301 basic medicineMicrobiology (medical)Antifungal Agents030106 microbiologyMicrobial Sensitivity TestsCandida parapsilosisAnidulafunginMicrobiologyCandida tropicalis03 medical and health sciencesEchinocandinsAmphotericin BAmphotericin BmedicineHumansPharmacology (medical)Candida albicansCandidaPharmacologyVoriconazolebiologyCandida glabrataChemistryCandidemiaDrug Synergismbiology.organism_classificationbacterial infections and mycosesCorpus albicansInfectious DiseasesBiofilmsAnidulafunginVoriconazolemedicine.drug
researchProduct

Antifungal prophylaxis: update on an old strategy.

2016

0301 basic medicineMicrobiology (medical)Antifungalmedicine.medical_specialtyAntifungal Agentsmedicine.drug_class030106 microbiologyMycoseAntifungal drugChemoprevention03 medical and health sciences0302 clinical medicineMedical microbiologyInternal medicineMedicineAntifungal AgentHumansMED/41 - ANESTESIOLOGIAbusiness.industry030208 emergency & critical care medicineGeneral MedicineInfectious DiseasesMycosesbusinessFluconazolemedicine.drugHuman
researchProduct

Antibiotic Resistance of Gram-Negative Bacteria from Wild Captured Loggerhead Sea Turtles

2020

Sea turtles have been proposed as health indicators of marine habitats and carriers of antibiotic-resistant bacterial strains, for their longevity and migratory lifestyle. Up to now, a few studies evaluated the antibacterial resistant flora of Mediterranean loggerhead sea turtles (Caretta caretta) and most of them were carried out on stranded or recovered animals. In this study, the isolation and the antibiotic resistance profile of 90 Gram negative bacteria from cloacal swabs of 33 Mediterranean wild captured loggerhead sea turtles are described. Among sea turtles found in their foraging sites, 23 were in good health and 10 needed recovery for different health problems (hereafter named wea…

0301 basic medicineMicrobiology (medical)Gram-negative bacteriaantibiotic resistanceSettore BIO/07030106 microbiologyZoologyBiochemistryMicrobiologyArticlebacterial ecology03 medical and health sciencesMarine bacteriophageMediterranean seaAntibiotic resistanceVibrionaceaeCaretta caretta; Mediterranean Sea; antibiotic resistance; bacterial ecology; feeding; marine bacteria; marine habitats; marine microbial ecologyAmpicillinmarine microbial ecologyMediterranean SeamedicinePharmacology (medical)General Pharmacology Toxicology and PharmaceuticsCaretta carettabiologySulfamethoxazolelcsh:RM1-950biology.organism_classification030104 developmental biologyInfectious Diseaseslcsh:Therapeutics. Pharmacologymarine bacteriamarine habitatmarine habitatsBacteria<i>Caretta caretta</i>feedingmedicine.drugAntibiotics
researchProduct

Performance of disc diffusion, MIC gradient tests and Vitek 2 for ceftolozane/tazobactam and ceftazidime/avibactam susceptibility testing of Pseudomo…

2021

AbstractObjectivesTo assess performance of disc diffusion, gradient tests and Vitek 2 system to determine the susceptibility of clinical Pseudomonas aeruginosa strains to ceftolozane/tazobactam (C/T) and ceftazidime/avibactam (CZA).MethodsTwo-hundred non-duplicate P. aeruginosa strains isolated by 47 French medical laboratories were selected to cover a wide range of C/T and CZA MICs. Performance of C/T disc (30/10 μg, Bio-Rad), CZA discs (10/4 μg) (Thermo Fisher and Bio-Rad), C/T and CZA gradient tests (Etest, BioMérieux; MIC Test Strip, Liofilchem), and AST-XN12 card of Vitek 2 system (BioMérieux) were compared with a broth microdilution (BMD) method (Thermo Fisher). MIC and disc results w…

0301 basic medicineMicrobiology (medical)TazobactamAvibactam030106 microbiologyCeftazidimeMicrobial Sensitivity Testsmedicine.disease_causeTazobactamCeftazidime03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineHumansPharmacology (medical)Pseudomonas Infections030212 general & internal medicineEtestPharmacologyChromatographyPseudomonas aeruginosaChemistryBroth microdilutionCeftazidime/avibactamAnti-Bacterial AgentsCephalosporinsDrug CombinationsInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyPseudomonas aeruginosaCeftolozaneAzabicyclo Compoundsmedicine.drug
researchProduct

Characteristics and Management of Candidaemia Episodes in an Established Candida auris Outbreak

2020

The multi-resistant yeast Candida auris has become a global public health threat because of its ease to persist and spread in clinical environments, especially in intensive care units. One of the most severe manifestations of invasive candidiasis is candidaemia, whose epidemiology has evolved to more resistant non-albicansCandida species, such as C. auris. It is crucial to establish infection control policies in order to control an outbreak due to nosocomial pathogens, including the implementation of screening colonisation studies. We describe here our experience in managing a C. auris outbreak lasting more than two and a half years which, despite our efforts in establishing control measure…

0301 basic medicineMicrobiology (medical)medicine.medical_specialty<i>Candida auris</i>colonisation030106 microbiologymultidrug-resistantyeastBiochemistryMicrobiology03 medical and health sciences0302 clinical medicineInternal medicineIntensive careAmphotericin BEpidemiologyInfection controlMedicinecandidaemiaPharmacology (medical)030212 general & internal medicineGeneral Pharmacology Toxicology and Pharmaceuticsoutbreakbusiness.industryMortality ratelcsh:RM1-950Outbreaklcsh:Therapeutics. PharmacologyInfectious DiseasesCandida aurissurveillancefungibusinessFluconazolemedicine.drugAntibiotics
researchProduct

Management of febrile neutropenia in the perspective of antimicrobial de-escalation and discontinuation.

2019

Introduction: Infections are among the most frequent complications in patients with hematological and oncological diseases. They might be classified as fever of unknown origin and microbiologically or clinically documented infections. Optimal duration of antimicrobial treatment is still unclear in these patients.Areas covered: We provide an overview on the management of febrile neutropenia in the perspective of antimicrobial de-escalation and discontinuation.Expert opinion: Patients with febrile high-risk neutropenia should be treated empirically with an anti-pseudomonal agent such as piperacillin/tazobactam. Several clinical studies support the assumption that the primary antibiotic regime…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyAntifungal Agents030106 microbiologyNeutropeniaMicrobiologyTazobactam03 medical and health sciencesAntimicrobial Stewardship0302 clinical medicineAnti-Infective AgentsVirologyMedicineHumans030212 general & internal medicineFever of unknown originIntensive care medicineFebrile Neutropeniabusiness.industryDrug Resistance Microbialmedicine.diseaseAntimicrobialDrug Resistance MultipleDiscontinuationAnti-Bacterial AgentsInfectious DiseasesDrug Therapy CombinationbusinessFebrile neutropeniaDe-escalationmedicine.drugPiperacillinExpert review of anti-infective therapy
researchProduct

Fast-Growing Alveolar Echinococcosis Following Lung Transplantation

2020

International audience; Alveolar echinococcosis is a rare but life-threatening infection caused by the parasiteEchinococcus multilocularis. Its natural history is characterized by a slow parasitic growth over several years. Increased incidence and shorter development delay have been reported in immune-compromised patients. We report the reactivation of aborted lesions within 12 months of lung transplantation leading to a fast-growing aggressive hepatic lesion. Timely identification of alveolar echninococcosis allowed prompt albendazole treatment and radical surgery leading to a favorable outcome 42 months after transplantation. However, close clinical, serological and radiological monitorin…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtymedicine.medical_treatment030231 tropical medicinelcsh:MedicineCase ReportEchinococcus multilocularisliverAlbendazole03 medical and health sciences0302 clinical medicinemedicinelung transplantationImmunology and AllergyLung transplantationRadical surgeryMolecular Biology<i>Echinococcus multilocularis</i>immunosuppressionGeneral Immunology and Microbiologybiologybusiness.industryIncidence (epidemiology)lcsh:RImmunosuppression030108 mycology & parasitologybiology.organism_classification3. Good healthSurgeryNatural historyTransplantationInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyparasiteEchinococcus multilocularisbusinessmedicine.drug
researchProduct

Ribosome-Targeting Antibiotics Impair T Cell Effector Function and Ameliorate Autoimmunity by Blocking Mitochondrial Protein Synthesis

2019

Summary While antibiotics are intended to specifically target bacteria, most are known to affect host cell physiology. In addition, some antibiotic classes are reported as immunosuppressive for reasons that remain unclear. Here, we show that Linezolid, a ribosomal-targeting antibiotic (RAbo), effectively blocked the course of a T cell-mediated autoimmune disease. Linezolid and other RAbos were strong inhibitors of T helper-17 cell effector function in vitro, showing that this effect was independent of their antibiotic activity. Perturbing mitochondrial translation in differentiating T cells, either with RAbos or through the inhibition of mitochondrial elongation factor G1 (mEF-G1) progressi…

0301 basic medicineMitochondrial translationmedicine.medical_treatmentT-LymphocytesCellMitochondrionmedicine.disease_causeRibosomemitochondrial translationOxidative PhosphorylationantibioticsAutoimmunityACTIVATIONMice0302 clinical medicineribosome-targetingMedicine and Health SciencesImmunology and AllergyTRANSCRIPTION FACTORMolecular Targeted TherapyMice Knockout0303 health sciencesEffectorExperimental autoimmune encephalomyelitisautoimmunityCell DifferentiationPeptide Elongation Factor GAnti-Bacterial Agents3. Good healthCell biologymitochondriaInfectious DiseasesCytokinemedicine.anatomical_structureRESPIRATION030220 oncology & carcinogenesisEncephalomyelitis Autoimmune ExperimentalMultiple SclerosisT cellImmunologyINHIBITIONT cellsBiologyOXAZOLIDINONEPeptides CyclicArticleMitochondrial Proteins03 medical and health sciencesNAD+medicineAnimalsHumanselongation factor G1030304 developmental biologyAutoimmune diseaseBacteriaLinezolidBiology and Life SciencesPATHWAYSDNANADmedicine.diseaseIn vitroMice Inbred C57BL030104 developmental biologyTh17 CellsArgyrinCHLORAMPHENICOLMEMBRANERibosomesImmunity
researchProduct

Rescuing the CFTR protein function: Introducing 1,3,4-oxadiazoles as translational readthrough inducing drugs.

2018

Nonsense mutations in the CFTR gene prematurely terminate translation of the CFTR mRNA leading to the production of a truncated protein that lacks normal function causing a more severe form of the cystic fibrosis (CF) disease. About 10% of patients affected by CF show a nonsense mutation. A potential treatment of this alteration is to promote translational readthrough of premature termination codons (PTCs) by Translational Readthrough Inducing Drugs (TRIDs) such as PTC124. In this context we aimed to compare the activity of PTC124 with analogues differing in the heteroatoms position in the central heterocyclic core. By a validated protocol consisting of computational screening, synthesis an…

0301 basic medicineModels MolecularCell SurvivalNonsense mutationCystic Fibrosis Transmembrane Conductance RegulatorSettore BIO/11 - Biologia MolecolareContext (language use)OxadiazoleSettore BIO/09 - FisiologiaCystic fibrosis03 medical and health sciencesStructure-Activity Relationship0302 clinical medicineDrug DiscoverymedicineHumansRNA MessengerGenetic disorderPharmacologyMessenger RNAOxadiazolesNonsense mutationDose-Response Relationship DrugMolecular StructureChemistryDrug Discovery3003 Pharmaceutical ScienceOrganic ChemistryTranslational readthroughPremature termination codonTranslation (biology)Settore CHIM/06 - Chimica OrganicaGeneral Medicinemedicine.diseaseSettore CHIM/08 - Chimica FarmaceuticaSmall moleculeCell biologySettore BIO/18 - Genetica030104 developmental biologyBiological targetCystic fibrosi030220 oncology & carcinogenesisHeLa CellsEuropean journal of medicinal chemistry
researchProduct